Today's word count is 671, or a 2-minute read.
President Trump and CMS administrator Seema Verma. Photo: Alex Wong/Getty Images
The Trump administration yesterday announced more changes designed to make Medicare Advantage more appealing and to lower prescription drug costs for seniors.
Why it matters: Although the proposal mainly tinkers around the edges, it could have a meaningful impact on some seniors' pocketbooks while furthering the administration's commitment to Medicare Advantage, a cash cow for insurers.
Details: The proposal aims to create more transparency within Medicare's prescription drug benefit, and to enhance price competition.
It also would allow all seniors with end-stage renal disease to enroll in Medicare Advantage, beginning in 2021.
Sen. Bernie Sanders still may eke out a win in Iowa, and is the consensus front-runner in New Hampshire.
Why it matters: At some point, it could become a failure of fiduciary duty.
Health care accounts for over 20% of all U.S. venture activity.
Few health care VCs Dan spoke with are working on a Plan B in the event of their risk/reward models being made obsolete. Three main reasons:
The bottom line: For now, health care venture's strategy is see no Bernie, hear no Bernie. We'll see how long that's viable.
The Centers for Disease Control and Prevention has shipped the diagnostic test for the novel coronavirus to more than 100 public health labs nationwide, allowing states to test for coronavirus cases themselves and receive results quicker, Axios' Marisa Fernandez writes.
Why it matters: The FDA bypassed usual regulatory channels to distribute the test under an Emergency Use Authorization, which has been used in life-threatening situations like MERS, Ebola and the Zika virus.
An international collaboration of scientists announced yesterday they have mapped out the cancer genome and also developed a new method of "carbon dating" cancer tumors to determine what and when mutations occurred that led to a person's cancer, Axios' Eileen Drage O'Reilly reports.
Why it matters: This meta-analysis of the whole genome is the first building block of a knowledge base that the scientists hope will help clinicians determine the precise treatment needed by individual patients — assuming the costs of sequencing and running algorithm programs continue to decline.
Photos: Mandel Ngan/AFP via Getty Images/New York Times archives
On the left: Executives from Juul, Reynolds, NJOY, Fontem and Logic in a Congressional hearing Tuesday, answering questions about the millions of teenagers addicted to nicotine.
On the right: Big Tobacco executives in April 1994 testified they didn't believe that cigarettes were addictive, "but that they would rather their own children did not smoke," per NYT.
Between the lines: There are huge differences between the two events, but it's still striking that more than 25 years later, we're once again reckoning with nicotine's threat to children.
Catch up fast, thanks to Marisa: